Our R&D vision is to combine world-class science and innovation to discover, develop, and deliver new medicines that make a difference and improve patients' lives.
AstraZeneca is one of the world’s leading investors in biopharmaceutical research and development. In 2008, the company invested nearly $5.2 billion on R&D.
We are committed to delivering more new, medically important and commercially successful medicines and vaccines to the market every year.
In this section:
- Our pipeline: We are sharply focused on making breakthroughs in therapeutic areas of the future
- Discovery & development: We are transforming cutting edge science into meaningful medicines
- External collaborations: We are continuously seeking opportunities with like-minded partners that share our commitment to pursuing novel medical solutions
- Research responsibility: We are committed to innovative scientific studies of the highest quality, conducted to the highest ethical standards
- Leading biologics and vaccines capabilities: 25% of our portfolio is now in biologics
- Clinical trials: We conduct clinical trials to help determine the safety and efficacy of a new medicine
- Postmarketing study commitments: We track our US postmarketing commitment studies' progress
- Seeking new medicines: Every new medicine is the result of an intensive and focused research process
- North American R&D sites: Our global R&D organization operates 11 R&D sites around the world, including three in North America
- Excellence in chemistry: To reward individuals who contribute to the art of chemistry, we annually present the Excellence in Chemistry Award, now in its 25th year
